Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Rotrosen

Showing results (111-120 of 157) with videos related to

Pageof 16
Sort By:
Drug and Alcohol Dependence|November 10, 2019
Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxoneLesia M Ruglass, Jennifer Scodes, Martina Pavlicova, et al.
Drug and Alcohol Dependence Reports|January 16, 2023
Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatmentYue Pan, Daniel J Feaster, Gabriel Odom, et al.
Journal of Substance Abuse Treatment|March 27, 2021
Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failureMatisyahu Shulman, Tse-Hwei Choo, Jennifer Scodes, et al.
Drug and Alcohol Dependence|August 21, 2023
Risks of returning to opioid use at treatment entry and early in opioid use disorder treatment: Role of non-opioid substancesFelipe Castillo, Mei-Chen Hu, Ying Liu, et al.
Psychiatry Research|September 23, 2003
Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidolErica Duncan, Sandor Szilagyi, Marion Schwartz, et al.
Addiction (Abingdon, England)|February 26, 2005
Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependenceAhmed Elkashef, Tyson H Holmes, Daniel A Bloch, et al.
Annals of Internal Medicine|December 18, 2018
Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid RelapseSean M Murphy, Kathryn E McCollister, Jared A Leff, et al.
Journal of Substance Abuse Treatment|August 9, 2021
Corrigendum to "Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse" [Journal of Substance Abuse Treatment 131 (2021) 108447]Miranda G Greiner, Matisyahu Shulman, Tse-Hwei Choo, et al.
Addiction Science & Clinical Practice|September 19, 2023
Implementation of substance use screening in rural federally-qualified health center clinics identified high rates of unhealthy alcohol and cannabis use among adult primary care patientsJennifer McNeely, Bethany McLeman, Trip Gardner, et al.
Journal of Substance Abuse Treatment|June 7, 2021
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapseMiranda G Greiner, Matisyahu Shulman, Tse-Hwei Choo, et al.
Pageof 16

Showing results (111-120 of 157) with videos related to

Sort By:
Pageof 16
Drug and Alcohol Dependence|November 10, 2019
Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxoneLesia M Ruglass, Jennifer Scodes, Martina Pavlicova, et al.
Drug and Alcohol Dependence Reports|January 16, 2023
Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatmentYue Pan, Daniel J Feaster, Gabriel Odom, et al.
Journal of Substance Abuse Treatment|March 27, 2021
Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failureMatisyahu Shulman, Tse-Hwei Choo, Jennifer Scodes, et al.
Drug and Alcohol Dependence|August 21, 2023
Risks of returning to opioid use at treatment entry and early in opioid use disorder treatment: Role of non-opioid substancesFelipe Castillo, Mei-Chen Hu, Ying Liu, et al.
Psychiatry Research|September 23, 2003
Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidolErica Duncan, Sandor Szilagyi, Marion Schwartz, et al.
Addiction (Abingdon, England)|February 26, 2005
Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependenceAhmed Elkashef, Tyson H Holmes, Daniel A Bloch, et al.
Annals of Internal Medicine|December 18, 2018
Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid RelapseSean M Murphy, Kathryn E McCollister, Jared A Leff, et al.
Journal of Substance Abuse Treatment|August 9, 2021
Corrigendum to "Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse" [Journal of Substance Abuse Treatment 131 (2021) 108447]Miranda G Greiner, Matisyahu Shulman, Tse-Hwei Choo, et al.
Addiction Science & Clinical Practice|September 19, 2023
Implementation of substance use screening in rural federally-qualified health center clinics identified high rates of unhealthy alcohol and cannabis use among adult primary care patientsJennifer McNeely, Bethany McLeman, Trip Gardner, et al.
Journal of Substance Abuse Treatment|June 7, 2021
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapseMiranda G Greiner, Matisyahu Shulman, Tse-Hwei Choo, et al.
Pageof 16